文献速递头颈外科

头颈癌

Head and Neck Cancer.
PubMed 文献 · Otolaryngol Head Neck Surg · 2016-11-14

本文评述头颈癌(HNC)近几十年死亡率未显著改善,而美国国立卫生研究院R01及等效基金按发病率归一化后,甲状腺癌(214美元)和HNC(1329美元)获资助最少;按死亡率调整后HNC在9种癌症中排第7(6138美元)。作者希望此文推动增加HNC研究投入的策略探索。

要点

  • HNC死亡率近几十年未显著改善,治疗手段扩展未转化为生存获益。
  • 按发病率归一化,甲状腺癌(214美元)和HNC(1329美元)获R01及等效基金最少。
  • 按死亡率调整后,HNC在9种评估癌症中资助排第7(6138美元)。

核心结论

  • HNC与其他癌症相比属于资助不足的疾病,近几十年死亡率未显著改善。
  • 由于含未成功申请的基金数据不公开,尚不清楚差异源于申请较少还是机会较少。
  • 作者希望此文推动探索增加HNC研究投入及支持受训者、早期和资深研究者的策略。

研究设计与样本

  • 本文为评论文章,基于美国国立卫生研究院R01及R01等效资助数据进行分析。

主要发现

  • 按发病率归一化,甲状腺癌获资助214美元,HNC获资助1329美元,二者获资助最少。
  • 按死亡率调整资助总额后,HNC在9种评估癌症中排第7,获资助6138美元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 含未成功申请的基金数据不公开,尚不清楚差异源于申请较少还是机会较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite a considerable expansion in our therapeutic repertoire for management of other malignancies, mortality from head and neck cancer (HNC) has not significantly improved in recent decades. Upon normalizing National Institutes of Health-awarded R01 and R01-equivalent grants by incidence, thyroid cancer ($214) and HNC ($1329) received the fewest funding dollars. Upon adjusting funding totals by mortality, HNC was 7th out of 9 cancers evaluated ($6138). These findings highlight HNC as an underfunded disease versus other cancers. As data detailing grant applications (including unsuccessful grants) are not publicly available, it is not clear if these disparities stem from fewer applications or fewer opportunities. Our hope is that this commentary will spur further investigation into strategies to increase HNC inquiry and funding for trainees as well as early-stage and established investigators.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Svider PF, Blasco MA, Raza SN, et al. Head and Neck Cancer. Otolaryngol Head Neck Surg. 2016. PMID: 28045631. doi:10.1177/0194599816674672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。